Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Diabetic patients are prone to diffuse and accelerated atherosclerosis, which increases the likelihood of requiring myocardial revascularization. Diabetes mellitus is a strong risk factor for restenosis following coronary stenting, with greater need for repeat revascularization and inferior clinical outcomes. Despite the recent advances in drug-eluting stent technology, diabetic patients are still at higher risk of adverse clinical events after coronary angioplasty. The focus of this review is to describe the evolution of the percutaneous management of diabetic patients with coronary artery disease and to define if any real progress has been made in terms of safety and efficacy with the use of the second generation drug-eluting stents in this high-risk population.

Original publication

DOI

10.1586/14779072.2014.930664

Type

Journal article

Journal

Expert Rev Cardiovasc Ther

Publication Date

08/2014

Volume

12

Pages

997 - 1003

Keywords

coronary angioplasty, diabetes mellitus, drug-eluting stents, outcome, restenosis, Angioplasty, Coronary Artery Disease, Coronary Restenosis, Diabetes Complications, Diabetes Mellitus, Drug-Eluting Stents, Humans, Risk Factors, Treatment Outcome